Table 5.
Estimated annual hospital and mortality costs due to AMR infections, Australia 2020.
| Organism | LOS (95%UI) | Hospital costsAUD (95% UI) | Premature mortality costAUD (95% UI) |
|---|---|---|---|
| 3GCR E. coli BSI | 1226 (683, 1952) |
$2,331,455 (1298900, $3710182) |
$ 26,841,346 ($1785903, $113191757) |
| 3GCR E. coli UTI | 5227 (2863, 8259) |
$9,936,130 ($5441984, $15701081) |
0 |
| 3GCR K. pneumoniae BSI |
1172 (616, 1941) |
$2,228,686 ($1170703, $3690599) |
$ 9,233,084 ($0, $ 45661523 |
| 3GCR K. pneumoniae UTI |
3185 (1755, 5021) |
$6,053,935 ($3335954, $9545555) |
0 |
| MRSA BSI | 12,818 (7246, 19966) |
$24,366,741 ($13774548, $37954686) |
$ 96,551,242 ($32060855, $ 212073885 |
| MRSA UTI | 1353 (754, 2157) |
$2,571,962 ($1433925, $4099885) |
$21,950,132 ($13049213, $87749865) |
| Ceftazidime-resistant P. aeruginosa BSI |
1336 (726, 2149) |
$2,540,257 ($1379668, $4085261) |
$ 23,804,876 ($1208018, $ 79475606) |
| Ceftazidime-resistant P. aeruginosa RTI |
5204 (2899, 8188) |
$9,892,433 ($5510956, $15566109) |
$ 181,003,565 ($78005482, $ 340995680) |
| Ceftazidime-resistant P. aeruginosa UTI |
8007 (4454, 12643) |
$15,220,906 ($8466204, $24,033,789) |
$ 28,786,073 ($0, $ 96489234) |
| VRE BSI | 1012 (547, 1647) |
$1,924,208 ($1040513, $3131419 ) |
$ 34,575,034 ($10677129, $74731089) |
| VRE UTI | 5336 (2917,8440) |
$10,143,051 ($5545878, $16044292) |
$ 15,797,700 (0, $ 58117278) |
| Total | 45,876 (25460, 70214) |
$71,988,858 ($48399233, $137562858) |
$438,543,052 ($13686600, $1108485917) |
3GCR: third-generation cephalosporin resistant; MRSA: methicillin-resistant Staphylococcus aureus, VRE: vancomycin-resistant E. faecium, BSI: bloodstream infection; UTI: urinary tract infection; RTI: respiratory tract infections, UI: uncertainty intervals; LOS: length of stay.
aValue of quality adjusted life year (QALY): $29,274 AUD.19